Harmony Biosciences Holdings (HRMY) said Monday it expects Q4 net product revenue of $201 million.
Analysts polled by FactSet expect $198.6 million.
The company reported preliminary 2024 net product revenue for the year ended Dec. 31 of $714 million, falling within its guidance for $700 million to $720 million.
Analysts surveyed by FactSet expect $712.1 million.
Harmony said it expects 2025 net product revenue of between $820 and $860 million. Analysts polled by FactSet expect $847.3 million.
Shares of the company were up more than 6% in recent Monday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。